Board summary
Key figures
28,767
Registered population
59.6% aged 18–64
21.1%
Aged 65+
ICB 14.9% · England 17.9%
16.5%
Ethnic minority (non-White)
9.2% Asian · England 9.6%
17.0%
In IMD quintile 1
ICB 40.7% · England 21.0%
~5,091
Core20 residents (est.)
Resident basis; registered basis ~5,210 · see page 3
4,616
Hypertension register
+3.65% in 3 yrs · England +5.60%
313
SMI register
12.5% of Bury (LAD)'s
641
COPD register
Reviews +5.38% in 3 yrs
Forecast to 2030
4,984
Hypertension patients, 2030
+368 on today
65.8%
QRISK ≥20% on statins, 2030
+2.25pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage trails England and borough.
Annual reviews reach 59.9% of 1,867 asthma patients (England 65.7%, about 750 unreviewed), contrasting with 2,263 asthma items per 1,000 aged 5-19.
Dementia register fell while national prevalence grew.
Recorded dementia prevalence (247 patients) fell 1.7% over 2023 to 2025 (England +6.0%, Bury (LAD) +1.2%), which could reflect review or coding gaps.
Under-80 hypertension blood pressure control rose strongly.
Under-80 blood pressure control rose +9.9% over 2023 to 2025 (England +3.2%, Bury (LAD) +6.4%), reaching 68.8% against 67.8% in England.
Population, age and ethnicity
Patients aged 65+ comprise 21.1% of the list, above borough and England benchmarks
Across constituent practices, WHITEFIELD DISTRICT & COMMUNITY PCN registers 28,767 patients. The demographic profile shows 21.1% (6,078 patients) aged 65+, compared to 17.6% in Bury (LAD), 14.9% in NHS Greater Manchester Integrated Care Board, and 17.9% in England. Adults aged 18–64 make up 59.6% (17,142 patients) and those aged 0–17 represent 19.3% (5,547 patients). Census usual-resident estimates in associated areas—not registered patients—show 83.5% White (Bury (LAD) 82.9%, ICB 76.4%, England 81.1%) and a 16.5% non-White share, led by 9.2% Asian or Asian British residents (Bury (LAD) 10.6%, ICB 13.6%, England 9.6%).
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bury (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bury LA) | 2,139 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bury LA) | 1,051 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bury LA) | 21.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 17.0% PCN-wide but spans an 18.2 pp practice range
The PCN Core20 share is 17.0%, below England (21.0%), Bury (LAD) (27.9%), and NHS Greater Manchester Integrated Care Board (40.7%), with an average IMD decile of 5.6. Practice shares span 18.2 pp, from 7.0% at Blackford House Medical Centre to 25.2% at The Elms Medical Centre. While weighted practice share is 18.1% (a 1.07 percentage point difference), Core20 volume centres on Unsworth Medical Centre (1,580 estimated patients), The Elms Medical Centre (1,566), and The Uplands Medical Practice (1,544).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
313
SMI register
1.07% recorded prevalence
202
Learning disability register
0.69% recorded prevalence
7
Care homes, 157 beds
In the PCN catchment
9.4%
Provide unpaid care
Bury (LAD), Census 2021
Recorded inclusion-health registers show 202 patients with a learning disability (0.7%, Bury (LAD) 0.6%, ICB 0.6%, England 0.6%) and 313 patients with severe mental illness (1.1%, Bury (LAD) 1.2%, ICB 1.1%, England 1.0%). Catchment data records 7 care homes with 157 beds, though occupancy and resident registration are not established by site capacity.
Severe mental illness: physical health checks
Across the 313-patient SMI register, 78.4% received a BP check (England 83.4%) and 77.2% a BMI check (England 82.1%). BP checks were 67.9% at The Uplands Medical Practice and 73.8% at The Elms Medical Centre.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,616
Hypertension register
+3.65%
Register growth, 3 yrs
Bury (LAD) +6.10% · England +5.60%
+6.23pp
BP control, under 80
≤140/90 · +1.41pp aged 80+
+368
More patients by 2030
Forecast 4,984 (16.98%)
Hypertension case-finding and control
Hypertension prevalence is 15.8% (4,616 patients), above England (15.2%) and the ICB (14.4%). Blood pressure control for patients under 80 reached 68.8% following a +9.9% change over 2023 to 2025, though The Uplands Medical Practice recorded 58.2%. Blood pressure control for patients aged 80 and over is 79.1%, trailing England (81.2%), Bury (LAD) (82.2%), and the ICB (83.2%). Lower control in older patients may reflect recall gaps, which clinical audit can test.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% is 61.0% (England 63.6%, Bury (LAD) 64.2%, ICB 67.0%). Statin coverage in diabetes without CVD is 72.3% (England 73.2%) and with CVD is 82.7% (England 84.4%). These gaps may indicate missed treatment opportunities to review locally.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 59,332 | £1.50 | £1.94 | £1.86 | £88,998 |
| Cardiovascular (all), 2025 | 81,844 | £2.85 | £3.15 | £3.33 | £233,255 |
In 2026, the PCN prescribed 59,332 lipid-regulating items at £1.50 per item (spend £88,998), below England (£1.86), Bury (LAD) (£1.91), and the ICB (£1.94), spending £21,360 less than at England's unit cost. Prescribing unit costs remain lower than comparators, though unit cost does not establish efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.52%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.45%
Asthma prevalence, PCN 3-yr % change
Asthma prescribing is 2,263 rate per 1,000 aged 5-19, above England (1,488 rate). Annual asthma review coverage is 59.9%, trailing England (65.7%) and Bury (LAD) (64.2%), leaving about 750 patients unreviewed across the 1,867-patient register. COPD review coverage is 73.3%, trailing England (76.4%) and Bury (LAD) (77.8%). Slower review completion alongside high symptom prescribing is consistent with reactive management, though unverified locally.
Cancer register and children's immunisation
The cancer register includes 1,301 patients (4.5% prevalence, England 3.8%). In Q1 2025/26, MMR dose 1 coverage at age 5 is 98.5% and dose 2 is 92.4% (a 6.1 pp difference), widening to a 14.3 pp difference at The Uplands Medical Practice. This drop-off could reflect recall attrition, unverified locally. Dose drop-off leaves children incompletely protected before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Whitefield District & Community PCN records a cancer prevalence of 4.5% (1,301 patients), above England (3.8%), Bury (LAD) (4.0%) and the ICB (3.3%). Cervical screening coverage for women aged 25-49 is 69.9% (England 66.8%), but three-year change is -2.8% (England -1.0%), standing at 65.3% at The Uplands Medical Practice. System-level early diagnosis describes the wider system rather than PCN performance: in 2022, NHS Greater Manchester ICB diagnosed 55.6% of known-stage cancers at stage 1 or 2 (England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028 (about 2,270 extra cases a year). Known stage was recorded for 70.8% of 16,492 registered cancers.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day cancer referral to treatment standard, showing a distance of -6.4 pp to the 85.0% standard, but ahead of NHS Greater Manchester Integrated Care Board (75.7%), Manchester University NHS Foundation Trust (72.8%), Bolton NHS Foundation Trust (69.7%) and England (71.2%). Its 28-day faster diagnosis standard reached 75.2%, meeting the 75.0% standard by 0.2 pp, though trailing the ICB (79.5%) and England (79.3%). For diagnostic tests, 15.7% waited 6+ weeks overall, while colonoscopy waiting 6+ weeks reached 40.0% (England 30.8%).
| Pathways within standard (%) | Northern Care Alliance | Bolton | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.50 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 69.66 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Bolton | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 2.05 | 11.68 | 21.40 |
| CT | 4.10 | 19.40 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 3.48 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.33 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 2.06 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 15.78 | 8.98 | 23.14 |
| Community services activity | Bury residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 58,875 | 573,310 |
| Referrals | 7,435 | 94,470 |
| Patients with a contact | 16,745 | 183,535 |
Community services (residents of Bury), Jun 2026 (provisional). In Jun 2026 (provisional), community health service activity recorded 58,875 contacts for Bury local authority residents. Adults aged 65 and over accounted for 25,735 contacts, representing a 43.7% share of all recorded community activity across the borough. These resident-level figures reflect wider system utilisation rather than PCN-level provision.
Practice variation and patient experience
Practice variation and patient experience
Overall QOF achievement ranges from 90.1% at The Elms Medical Centre to 95.3% at Blackford House Medical Centre (England 92.5%). Across practices, vaccination and immunisation achievement varies by 21.2 pp: The Uplands Medical Practice achieved 45.1% while Unsworth Medical Centre reached 66.3% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Unsworth | 120 | 21.3 | 81.8% | 66.0% | 83.5% |
| Blackford House | 106 | 7.0 | 60.2% | 81.1% | 79.0% |
| Uplands Medical | 108 | 20.1 | 53.1% | 81.4% | 72.2% |
| Elms | 119 | 25.2 | 49.8% | 75.6% | 71.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trail England, while dementia and stroke registers declined
Over 2023 to 2025, 12 of 25 compared measures trailed England. Smoking cessation support fell 5.8 pp (England +0.1 pp) to 92.7%. Dementia register prevalence change was -1.7% (England +6.0%), and stroke prevalence change was -1.3% (England +2.3%). Conversely, heart failure reviews grew +11.7% (England +8.7%) to 82.1%, blood pressure control under 80 rose +9.9% (England +3.2%), and alcohol recording in psychosis rose +10.3 pp (England +5.4 pp). Slower register growth could reflect under-detection or coding practices rather than lower need, unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Smoking support (SMI)
Stroke register
QRISK statin treatment
Asthma register
BP control, under 80
Hypertension BP reading
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bury (LAD) | Asset | PCN | Bury (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (157 beds) | n/a | Schools (catchment) | 37 | n/a |
| Children's centres | 1 | 8 | Places of worship | 22 | 107 |
| Libraries | 2 | 12 | Primary schools (LA maintained) | 6 | 25 |
| Primary academies | 7 | 33 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Annual asthma review coverage is 59.9% across 1,867 patients, below England (65.7%) and Bury (LAD) (64.2%), leaving about 750 patients unreviewed. For discussion: the PCN could run structured asthma review recall using a single template and after-school slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health checks
Across 313 SMI patients, 12-month BP recording is 78.4% (England and ICB 83.4%) and BMI is 77.2% (England 82.1%), with BP at 67.9% at The Uplands Medical Practice. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Dementia case-finding and coding review
Dementia prevalence is 0.8% (247 patients; unadjusted gap range -22 to +9 against England 0.8% and Bury (LAD) 0.9%) and fell 1.7% over 2023 to 2025 (England +6.0%). Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult case-finding review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertensive blood pressure review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Dementia case-finding and coding review (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
